Source: Annual Congress 2008 - Lung and bone marrow transplantation: miscellaneous

Abstract

Background Advanced lung disease causes premature mortality in CF. Lung transplantation offers a 10-year survival of over 50% in experienced centres. A decision to list for transplant is based upon many factors though no objective measurement of patient reported quality of life (QOL) occurs.Aim To evaluate an objective measure of QOL in patients with advanced CF lung disease attending for lung transplant assessment.Method 48 Patients attending for transplant assessment completed the Short Form 36 (SF36). The score was then correlated with disease severity and transplant assessment outcome.Results Median age: 25 yrs (16-51); median FEV1: 25% pred. (11-47); median Pa02: 8.9 kPa (6.7-14); mean six minute walk distance (6MWD): 470m (65-770). Median BMI: 18.8kg/m2 (14-24). A wide range of QOL scores was noted: Total SF36 ranged from 17-89; Physical health domain 5-83; Mental health domain 14-89. 26 patients were listed and had significantly worse FEV1 predicted 20% vs 29% ; p<0.01. Median Pa02 8.2kPa (6.7-14) vs 9.75kPa (8.3-12.9); p<0.01. There were no significant differences in 6MWD and BMI. QOL was poorer in the listed group: Median Total SF36 41 (17-81) vs 59 (23-89); p=0.043 with poorer scores in the mental health domain: Median score 43 (14-78) vs 61 (25-89); p=0.03. Physical health was not significantly poorer: Median 29.5 (5-73) vs 48.5 (10-83); p=0.06.Conclusions Wide variability in QOL was reported by the cohort. Those listed had worse lung function but similar exercise capacity. QOL is poorer in those listed particularly in the mental health domain. This may influence listing decisions. Future studies of CF specific QOL measures, SF-36 and survival may be useful.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Doe, A. De Soyza, J. Lordan, A. Fisher, P. Corris (Newcastle-upon Tyne, United Kingdom). Patient reported quality of life in advanced cystic fibrosis (CF) lung disease assessed for lung transplantation. Eur Respir J 2008; 32: Suppl. 52, 1627

Member's Comments

No comment yet.

Related content which might interest you: Quality of life in cystic fibrosis patients before and after lung transplantation: a longitudinal study Source: Eur Respir J 2002; 20: Suppl. 38, 343s Year: 2002 Factors affecting lung function in adult cystic fibrosis patients after lung transplantation. Source: International Congress 2018 – Evolving approaches to differential diagnosis Year: 2018 Treatment of advanced cystic fibrosis lung disease and end of life decisions Source: School Course 2013 - Cystic Fibrosis Year: 2013 Does lung transplantation affect on the improvement of psychological status in patients with adult cystic fibrosis? Source: International Congress 2018 – Contemporary respiratory care: symptoms, the role of the nurse and the organisation of care Year: 2018 Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020 Year: 2021 Better survival outcomes after bilateral lung transplantation compared to single lung transplantation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 Improved survival at low lung function in cystic fibrosis (CF) Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Pretransplant factors influencing survival in cystic fibrosis (CF) patients after lung transplantation (LTx) Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006 Survival and lung function in double lung transplant recipients with cystic fibrosis Source: International Congress 2017 – From donor lung selection and organ preservation to lung transplant outcome Year: 2017 Impact of surgery on quality of life in bronchogenic carcinoma operated patients Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Exercise tolerance in children with cystic fibrosis undergoing lung transplantation assessment Source: Eur Respir J 2001; 18: 293-297 Year: 2001 Outcomes and survival following lung transplantation in non-cystic fibrosis bronchiectasis Source: ERJ Open Res, 8 (1) 00607-2021; 10.1183/23120541.00607-2021 Year: 2022 CF lung disease and lung transplantation Source: ERS Course 2018 - Summer school of paediatric respiratory medicine Year: 2018 CF lung disease and lung transplantation Source: ERS Course 2019 - Summer school of paediatric respiratory medicine 2019 Year: 2019 Progression of lung involvement in patients with cystic fibrosis (CF), assessed by longitudinal respiratory function measurements Source: Eur Respir J 2002; 20: Suppl. 38, 20s Year: 2002 CF lung disease and lung transplantation Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017 Predictors of quality of life in patients with interstitial lung disease Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease Year: 2009 The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Cystic fibrosis lung disease and lung transplantation Source: ERS Skills Course 2016 Year: 2016